ZURICH, April 24 Drug ingredients maker Lonza
will replace biotech company Actelion in
Switzerland's blue-chip SMI stock index, the Swiss stock
exchange said on Monday.
The change will take effect on May 3, Switzerland's SIX
exchange said in a statement.
U.S. healthcare giant Johnson & Johnson is buying
Actelion in a $30 billion all-cash deal. Analysts had considered
Lonza the favourite to replace Actelion ahead of the likes of
construction chemicals specialist Sika and hearing aid
(Reporting by Joshua Franklin; Editing by Adrian Croft)